0 0 0 0 0 0 0.000163871743049113 0.000163871743049113
Sign Up Today X
Thanks for submitting the form.
Stockreport

Biogen Details West Coast Hub, Felzartamab Phase 3 Plans and AMR Readout Timeline at Conference [Yahoo! Finance]

Biogen Inc. (BIIB)  More Company Research Source: Yahoo! Finance
Last biogen inc. earnings: 4/22 07:12 am Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
the team from about 45 to 100+ employees and launching three Phase 3 studies over the past year. Biogen has positioned antibody-mediated rejection (AMR) as the lead indication after a Phase 2 showing 80% histologic reversal; a 120-patient global Phase 3 with a six-month primary endpoint is enrolling, with a topline readout expected next year and Breakthrough/Orphan designations in place. Felzartamab is also in Phase 3 for IgA nephropathy and primary membranous nephropathy and in Phase 2 for microvascular inflammation (MVI), while Biogen pursues a subcutaneous formulation and next-generation anti-CD38 to support commercialization concentrated at major transplant and glomerular centers. Interested in Biogen Inc.? Here are five stocks we like better. 3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 Biogen (NASDAQ:BIIB) outlined its growing “West Coast Hub” and development plans for felzartamab, an anti-CD38 antibody being studied across multiple kidney-related immuno [Read more]
IMPACT SNAPSHOT EVENT TIME: BIIB
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BIIB alerts
from News Quantified
BIIB
NEWS
BIIB
Earnings
BIIB
Analyst Actions
BIIB
SEC Filings
Stockreport

Biogen Details West Coast Hub, Felzartamab Phase 3 Plans and AMR Readout Timeline at Conference [Yahoo! Finance]

Biogen Inc.  (BIIB) 
More Company Research Source: Yahoo! Finance
Last biogen inc. earnings: 4/22 07:12 am Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
the team from about 45 to 100+ employees and launching three Phase 3 studies over the past year. Biogen has positioned antibody-mediated rejection (AMR) as the lead indication after a Phase 2 showing 80% histologic reversal; a 120-patient global Phase 3 with a six-month primary endpoint is enrolling, with a topline readout expected next year and Breakthrough/Orphan designations in place. Felzartamab is also in Phase 3 for IgA nephropathy and primary membranous nephropathy and in Phase 2 for microvascular inflammation (MVI), while Biogen pursues a subcutaneous formulation and next-generation anti-CD38 to support commercialization concentrated at major transplant and glomerular centers. Interested in Biogen Inc.? Here are five stocks we like better. 3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 Biogen (NASDAQ:BIIB) outlined its growing “West Coast Hub” and development plans for felzartamab, an anti-CD38 antibody being studied across multiple kidney-related immuno [Read more]
IMPACT SNAPSHOT
EVENT TIME:
BIIB
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS